241 Stock Overview
An investment holding company, engages in the pharmaceutical direct sales, pharmaceutical e-commerce platform, and healthcare and digital services businesses in Mainland China and Hong Kong.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 4/6 |
Past Performance | 4/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Alibaba Health Information Technology Limited Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | HK$2.87 |
52 Week High | HK$5.08 |
52 Week Low | HK$2.59 |
Beta | 1.02 |
11 Month Change | -10.87% |
3 Month Change | -24.07% |
1 Year Change | -38.15% |
33 Year Change | -78.13% |
5 Year Change | -59.52% |
Change since IPO | 124.22% |
Recent News & Updates
Alibaba Health Information Technology (HKG:241) Is Looking To Continue Growing Its Returns On Capital
Jul 03After Leaping 26% Alibaba Health Information Technology Limited (HKG:241) Shares Are Not Flying Under The Radar
Jun 07Recent updates
Alibaba Health Information Technology (HKG:241) Is Looking To Continue Growing Its Returns On Capital
Jul 03After Leaping 26% Alibaba Health Information Technology Limited (HKG:241) Shares Are Not Flying Under The Radar
Jun 07Alibaba Health Information Technology's (HKG:241) Solid Earnings Are Supported By Other Strong Factors
Jun 06Risks Still Elevated At These Prices As Alibaba Health Information Technology Limited (HKG:241) Shares Dive 26%
Apr 21Is Now The Time To Look At Buying Alibaba Health Information Technology Limited (HKG:241)?
Apr 16Alibaba Health Information Technology (HKG:241) Might Have The Makings Of A Multi-Bagger
Mar 29Is There An Opportunity With Alibaba Health Information Technology Limited's (HKG:241) 36% Undervaluation?
Mar 12With A 25% Price Drop For Alibaba Health Information Technology Limited (HKG:241) You'll Still Get What You Pay For
Jan 17Is Now An Opportune Moment To Examine Alibaba Health Information Technology Limited (HKG:241)?
Jan 07Returns On Capital Are Showing Encouraging Signs At Alibaba Health Information Technology (HKG:241)
Dec 15Shareholders Should Be Pleased With Alibaba Health Information Technology Limited's (HKG:241) Price
Sep 28Alibaba Health Information Technology Limited's (HKG:241) Intrinsic Value Is Potentially 25% Below Its Share Price
Jul 02Is Alibaba Health Information Technology Limited (HKG:241) Potentially Undervalued?
Jun 11Estimating The Fair Value Of Alibaba Health Information Technology Limited (HKG:241)
Jun 22Is There An Opportunity With Alibaba Health Information Technology Limited's (HKG:241) 49% Undervaluation?
Dec 01Alibaba Health Information Technology (HKG:241) Is Looking To Continue Growing Its Returns On Capital
Oct 15Estimating The Fair Value Of Alibaba Health Information Technology Limited (HKG:241)
Aug 12Alibaba Health Information Technology (HKG:241) Is Doing The Right Things To Multiply Its Share Price
Jun 25These Analysts Just Made A Huge Downgrade To Their Alibaba Health Information Technology Limited (HKG:241) EPS Forecasts
May 30Earnings Report: Alibaba Health Information Technology Limited Missed Revenue Estimates By 6.8%
May 27The Return Trends At Alibaba Health Information Technology (HKG:241) Look Promising
Mar 23Should You Be Adding Alibaba Health Information Technology (HKG:241) To Your Watchlist Today?
Mar 05How Much Are Alibaba Health Information Technology Limited (HKG:241) Insiders Taking Off The Table?
Feb 15Are Alibaba Health Information Technology's (HKG:241) Statutory Earnings A Good Reflection Of Its Earnings Potential?
Jan 31If You Had Bought Alibaba Health Information Technology (HKG:241) Stock Three Years Ago, You Could Pocket A 457% Gain Today
Dec 31Has Alibaba Health Information Technology Limited's (HKG:241) Impressive Stock Performance Got Anything to Do With Its Fundamentals?
Dec 16Will Alibaba Health Information Technology's (HKG:241) Growth In ROCE Persist?
Dec 01Shareholder Returns
241 | HK Consumer Retailing | HK Market | |
---|---|---|---|
7D | 0.7% | 0.7% | -2.9% |
1Y | -38.1% | -45.1% | -1.5% |
Return vs Industry: 241 exceeded the Hong Kong Consumer Retailing industry which returned -44.9% over the past year.
Return vs Market: 241 underperformed the Hong Kong Market which returned 0% over the past year.
Price Volatility
241 volatility | |
---|---|
241 Average Weekly Movement | 6.4% |
Consumer Retailing Industry Average Movement | 6.4% |
Market Average Movement | 6.3% |
10% most volatile stocks in HK Market | 13.1% |
10% least volatile stocks in HK Market | 3.3% |
Stable Share Price: 241's share price has been volatile over the past 3 months.
Volatility Over Time: 241's weekly volatility (6%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1998 | 1,435 | Difan Shen | www.alihealth.cn |
Alibaba Health Information Technology Limited, an investment holding company, engages in the pharmaceutical direct sales, pharmaceutical e-commerce platform, and healthcare and digital services businesses in Mainland China and Hong Kong. The company offers a range of prescription and over-the-counter drugs, nutritional supplements, medical devices, contact lenses, health food, adult and family planning products, healthcare and skincare products, and various other health-related products. It also provides medical and healthcare services, including medical checkups, nucleic acid testing, medical consultation, appointment-booking, vaccination, dental care, mental care, optometry, and nursing services, as well as traditional Chinese medicines.
Alibaba Health Information Technology Limited Fundamentals Summary
241 fundamental statistics | |
---|---|
Market cap | HK$46.15b |
Earnings (TTM) | HK$968.00m |
Revenue (TTM) | HK$29.61b |
47.7x
P/E Ratio1.6x
P/S RatioIs 241 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
241 income statement (TTM) | |
---|---|
Revenue | CN¥27.03b |
Cost of Revenue | CN¥21.13b |
Gross Profit | CN¥5.90b |
Other Expenses | CN¥5.01b |
Earnings | CN¥883.48m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | 0.055 |
Gross Margin | 21.81% |
Net Profit Margin | 3.27% |
Debt/Equity Ratio | 0% |
How did 241 perform over the long term?
See historical performance and comparison